Formyl peptide receptors (FPRs) are G-protein-coupled receptors that play an important role in the regulation of inflammatory process and cellular dysfunction. In humans, three different isoforms are expressed (FPR1, FPR2, and FPR3). FPR2 appears to be directly involved in the resolution of inflammation, an active process carried out by specific pro-resolving mediators that modulate specific receptors. Previously, we identified 2-arylacetamido pyridazin-3(2H)-ones as FPR1-or FPR2-selective agonists, as well as a large number of mixed-agonists for the three isoforms. Here, we report a new series of 2-arylacetamido pyridazinones substituted at position 5 and their development as FPR agonists. We also synthesized a new series of 2-oxothiazolones bearing a 4-bromophenylacetamido fragment, which was fundamental for activity in the pyridazinone series. The compounds of most interest were 4a, a potent, mixed FPR agonist recognized by all three isotypes (FPR1 EC 50 5 19 nM, FPR2 EC 50 5 43 nM, FPR3 EC 50 5 40 nM), and 4b, which had potent activity and a preference for FPR2 (EC 50 5 13 nM). These novel compounds may represent valuable tools for studying FPR activation and signaling. Drug Dev Res 78 : 49-62, 2017.
INTRODUCTION
Inflammation is a primary response of the immune system to injury or infection by invading microbial pathogens and is mediated by the action of many cell types with distinct functions [Beutler, 2004] . The critical role of the inflammatory process in health and disease is essential; however, the mechanisms leading to the restoration of homeostasis and resolution of inflammation (ROI) have only recently been elucidated. These studies have demonstrated that the ROI is an active process carried out by specific pro-resolving mediators, such as lipoxin, resolvins, protectins, and maresins, which have antiinflammatory and pro-resolving activities that are mediated via interactions with specific receptors [Serhan et al., 2002; Serhan and Levy, 2003; Serhan et al., 2011; Serhan et al., 2015] . Among the receptors activated by pro-resolving mediators is formyl peptide receptor 2 (FPR2), which belongs to a group of G-protein coupled receptors [Corminboeuf and Leroy, 2015] . In addition to FPR2, two other isoforms, FPR1 and FPR3, have been identified in humans and exhibit a high level of amino acid homology with FPR2 . Despite their high level of sequence homology, the FPRs differ in their ability to bind the prototypic N-formyl peptide N-formyl-methionine-leucine-phenylalanine (fMLF). FPR1 has high affinity receptor for this ligand, FPR2 lowaffinity receptor, while FPR3 does not bind fMLF. FPR1 and FPR2 have a similar distribution in a variety of tissues and cells involved in inflammation, including endothelial cells, platelets and immature dendritic cells, monocytes, neutrophils, macrophages, T lymphocytes, and epithelial cells [Migeotte et al., 2006; Ye et al., 2009] , whereas FPR3 is expressed in monocytes and dendritic cells [Migeotte et al., 2005 [Migeotte et al., , 2006 .
The involvement of FPR2 in the ROI makes this receptor an attractive target for treating a variety of pathologies, including rheumatoid arthritis, asthma, chronic obstructive pulmonary disease, cancer, cardiovascular, and Alzheimer's diseases [Libby, 2002 [Libby, , 2015 Mantovani et al., 2008; Bozinovski et al., 2013] . There are only a few reported examples of FPR2-selective ligands [Schepetkin et al., 2014a] .
Our research in the field of FPR ligands led to the identification of a large number of pyridazin-3(2H)-one derivatives that were mixed FPR1/FPR2 agonists ( Fig. 1 , general structure A) [Cilibrizzi et al., 2009 [Cilibrizzi et al., , 2012 Cilibrizzi et al., 2013; Crocetti et al., 2013; Giovannoni et al., 2013 , Vergelli et al., 2016 . Key requirements for activity were the presence of a methyl group at position 6 of the pyridazinone ring, a 4-bromophenylacetamide moiety at N-2, and a benzyl/ aniline group at position 4 of the scaffold. In the series of 4-anilino derivatives, we identified some compounds with good potency and with a moderate preference for FPR2 subtype [Vergelli et al., 2016] . In the present article, we further investigated 4-benzylpyridazinones derivatives as isosteres of the 4-anilino derivatives and examine their structure-activity relationships [Vergelli et al., 2016] , as well as several derivatives lacking a benzyl fragment at position 4. We also synthesized and evaluated a series of 2-oxothiazolones by maintaining the 4-bromophenylacetamide side fragment.
MATERIALS AND METHODS

Chemistry
The synthetic pathways followed to obtain the final compounds are shown in Figures 2 and 3 , and the structures were confirmed by analytical and spectral data.
In Figure 2 , synthesis of the 4-benzylpyridazinones 4a-f and the 4-unsubstituted derivatives of type 6 and 7 is presented. Previously described oxoacids 1a-e [Metz and Schwenker, 1980; Xu et al., 2005; Holloway et al., 2010] were reacted with hydrazine hydrate to obtain the corresponding 4,5-dihydropyridazinones (6)2a-e (compounds (6)2a,b,d [Pinna et al., 1988; Haider and Holzer, 2004; Xu et al., 2005] ), which were converted into derivatives 3a-f by treatment with the appropriate arylaldehyde in the presence of KOH. Alkylation of 3a-f with commercially available N-(4-bromophenyl)22-chloroacetamide in anhydrous CH 3 CN resulted in the final compounds 4a-f. Compounds (6)2a,b [Pinna et al., 1988; Haider and Holzer, 2004] were also key intermediates for the synthesis of 4-unsubstituted derivatives 6 and 7 by direct alkylation with N-(4-bromophenyl)22-chloroacetamide (compounds 6a,b) or by oxidation with Br 2 and acetic acid (compounds 5a,b) [Coates and McKillop, 1993; Haider and Holzer, 2004] and further alkylation (7a,b).
In Figure 3 , synthesis of the final oxothiazolones 9a-h and 10 is presented. The previously described compounds 8a-h [Isomura et al., 1988; Pihlaja et al., Fig. 2 . Synthesis of the final compounds 4a-f, (6)6a,b, 7a,b. Reagents and conditions: (i) N 2 H 4 H 2 O, EtOH, reflux, 3h; (ii) 3 or 4-methoxybenzaldehyde, KOH 5% (w/v) in anhydrous EtOH, reflux, 7-20 h; (iii) N-(4-bromophenyl)-2-chloroacetamide, K 2 CO 3 , anhydrous CH 3 CN, reflux, 5-7 h; (iv) Br 2 /AcOH, reflux, 8h.
2002; Wang et al., 2005; Yarligan et al., 2005; Zhao et al., 2013] were alkylated as shown to obtain the desired 9a-h. The final 9h was then subject to catalytic reduction with Pd/C in a Parr instrument to obtain compound 10.
Experimentals
Reagents and starting materials were obtained from commercial sources. Extracts were dried over Na 2 SO 4 , and the solvents were removed under reduced pressure. All reactions were monitored by thin layer chromatography (TLC) using commercial plates pre-coated with Merck silica gel 60 F-254, and visualization was performed by UV fluorescence (k max 5 254 nm) or by staining with iodine or potassium permanganate. Chromatographic separations were performed on a silica gel column using gravity chromatography (Kieselgel 40, H NMR are given in Hz and were calculated using "TopSpin 1.3" software and rounded to the nearest 0.1 Hz. Microanalyses were performed with a Perkin-Elmer 260 elemental analyzer for C, H, and N, and the results were within 6 0.4% of the theoretical values, unless otherwise stated.
General Procedures for (6)2c and (6)2e
To a solution of appropriate acid 1c and 1e (1.52 mmol) [Holloway et al., 2010] in EtOH (5 mL), hydrazine hydrate (3.04 mmol) was added. The mixture was refluxed for 3 h. After cooling, the solvent was evaporated under vacuum and cold water (10 mL) was added. The suspension was extracted with CH 2 Cl 2 (3 3 15 mL), the organic phase was dried over Na 2 SO 4 and evaporated to give the final compounds (6)2c and (6)2e.
(6)5-Ethyl-6-Methyl-4,5-Dihydropyridazin-3(2H)-One, (6)2c H, 8.63; N, 19.98; Found: C, 59.85; H, 8.65; N, 19.92 .
Yield 5 34%; mp 5 63-678C (Cyclohexane H, 9.59; N, 16.65; Found: C, 64.41; H, 9.58; N, 16.59 .
General Procedures for 3a-f
To a solution of the suitable intermediate (6)2a-e ((6)2a,b and (6)2d [Pinna et al., 1988; Haider and Holzer, 2004; Xu et al., 2005] ) (1.44 mmol) in 5-9 mL of KOH/absolute EtOH (5% w/v), 3-or 4-methoxybenzaldehyde (1.44-2.16 mmol) was added and the mixture was refluxed under stirring for 7-20 h. After cooling, the mixture was concentrated in vacuo, diluted with ice-cold water (5-10 mL), neutralized with N HCl and extracted with CH 2 Cl 2 (3 3x 20 mL). Removal of the solvent resulted in crude compounds 3a,b,f, which were purified by flash chromatography using cyclohexane/ethyl acetate 1:3 (for 3a,b) and cyclohexane/ethyl acetate 2:1 (for 3f) as eluents. Compounds 3c-e were recovered as crude precipitate after dilution and neutralization. These final compounds were purified by crystallization from EtOH.
Yield 5 58%; mp 5 185-1868C (EtOH H, 6.60; N, 11.47; Found: C, 69.01; H, 6.59; N, 11.50 .
Yield 5 44%; mp 5 150-1518C (EtOH H, 6.60; N, 11.47; Found: C, 68.99; H, 6.59; N, 11.49 .
Yield 5 44%; mp 5 168-1708C (EtOH). 
4-(
Yield 5 23%; mp 5 134-1378C (EtOH H, 7.40; N, 10.29; Found: C, 70.39; H, 7.41; N, 10.23 .
Yield 5 H, 7.74; N, 9.78; Found: C, 71.49; H, 7.75 ; N, 9.81.
Yield 5 32%; oil. 
General Procedures for 4a-f
To a mixture of the appropriate intermediate 3a-f (0.40 mmol) and K 2 CO 3 (0.80-1.20 mmol) in CH 3 CN (5-10 mL), N-(4-bromophenyl)22-chloroacetamide (0.40-0.72 mmol) was added and the suspension was refluxed under stirring for 5-7 h. After cooling, the mixture was concentrated in vacuo, ice cold water was (5-10 mL) added and then further stirred for 1 h. The precipitate was recovered by suction and purified by flash chromatography using cyclohexane/ethyl acetate 1:1 (compounds 4a,b,e), cyclohexane/ethyl acetate 1:2 (compounds 4c,d) and cyclohexane/ethyl acetate 2:1 for 4f as eluents.
Yield 5 48%; mp 5 123-1248C (EtOH). H, 4.86; N, 9.21; Found: C, 57.74; H, 4.85; N, 9.24 .
Yield 5 58%; mp 5 177-1788C (EtOH). H, 4.86; N, 9.21; Found: C, 57.69; H, 4.85; N, 9.18 .
Yield 5 39%; mp 5 86-888C (EtOH H, 5.14; N, 8.93; Found: C, 58.89; H, 5.13; N, 8.90 .
Yield 5 30%; mp 5 81-838C (EtOH H, 5.41; N, 8.67; Found: C, 59.67; H, 5.40; N, 8.64 .
Yield 5 57%; mp 5 75-778C (Cyclohexane H, 5.66; N, 8.43; Found: C, 60.08; H, 5.66; N, 8.46 .
Yield 5 24%; oil. H, 4.67; N, 8.11; Found: C, 62.74; H, 4.68; N, 8.13 .
General Procedures for (6)6a,b and 7a,b
Compounds (6)6a,b and 7a,b were obtained starting from appropriate substrates (6)2a,b [Pinna et al., 1988; Haider and Holzer, 2004] and 5a,b [Coates and McKillop, 1993; Haider and Holzer, 2004 ] following the same procedure described for 4a-f. The final compounds were purified by column chromatography using cyclohexane/ethyl acetate 1:1 as eluent.
Yield 5 36%; mp 5 84-858C (EtOH). H, 4.77; N, 12.42; Found: C, 49.59; H, 4.75; N, 12.47 .
Yield 5 62%; oil. H, 4.20; N, 12.50; Found: C, 50.16; H, 4.19; N, 12.53 .
Yield 5 64%; mp 5 199-2008C (EtOH). 
General Procedures for 9a-h
Compounds 9a-h were obtained starting from appropriate substrate of type 8 [Isomura et al., 1988; Pihlaja et al., 2002; Wang et al., 2005; Yarligan et al., 2005; Zhao et al., 2013] following the same procedure described for 4a-f. The final compounds were purified by column chromatography using cyclohexane/ethyl acetate 1:1 (for 9a,f,g), cyclohexane/ethyl acetate 1:2 (for 9b), cyclohexane/ethyl acetate 2:1 (for 9d), and CH 2 Cl 2 /CH 3 OH 98:2 (9c,e) as eluents.
2-(5-acetyl-4-methyl-2-oxo-thiazol-3-yl)-N-(4-bromophenyl)Acetamide, 9a 
Yield 5 25%; mp 5 162-1658C (EtOH 
2-[4-(4-
Compound 9h (0.11 mmol) was subject to catalytic reduction with 10% Pd/C (0.05 mmol) in EtOH (20 mL) for 2 h in a Parr instrument (30 PSI). The catalyst was filtered off, and the solvent was evaporated under vacuum, affording the final compound, which was purified by column chromatography using cyclohexane/ethyl acetate 1:1 as eluent. Yield 5 27%; mp 5 188-1898C (EtOH). H, 3.49; N, 10.39; Found: C, 50.61; H, 3.48; N, 10.37 .
Cell Culture
Human promyelocytic leukemia HL60 cells stably transfected with FPR1 (FPR1-HL60), FPR2 (FPR2-HL60), or FPR3 (FPR3-HL60) were cultured in RPMI 1640 medium supplemented with 10% heat-inactivated fetal calf serum, 10 mM HEPES, 100 lg/ml streptomycin, 100 U/ml penicillin, and G418 (1 mg/mL), as previously described . Rat basophilic leukemia (RBL-2H3) cells transfected with mouse Fpr1 (Fpr1-RBL) or mouse Fpr2 (Fpr2-RBL) were cultured in DMEM supplemented with 20% (v/v) fetal bovine serum (FBS), 10 mM HEPES, 100 lg/ml streptomycin, 100 U/ml penicillin, and G418 (250 lg/ml). Wild-type HL60 and RBL-2H3 cells were cultured under the same conditions, but without G418.
Isolation of Human Neutrophils
Blood was collected from healthy donors in accordance with a protocol approved by the Institutional Review Board at Montana State University. Neutrophils were purified from the blood using dextran sedimentation, followed by Histopaque 1077 gradient separation and hypotonic lysis of red blood cells, as previously described [Schepetkin et al., 2014b] . Isolated neutrophils were washed twice and resuspended in HBSS without Ca 21 and Mg
(HBSS 2
). Neutrophil preparations were routinely > 95% pure, as determined by light microscopy, and greater than 98% viable, as determined by trypan blue exclusion.
Isolation of Murine Neutrophils
Murine bone marrow neutrophils were isolated from bone marrow leukocyte preparations, as described previously [Schepetkin et al., 2014a] .
Briefly, bone marrow leukocytes were flushed from tibias and femurs of BALB/c mice with HBSS, filtered through a 70 lm nylon cell strainer (BD Biosciences, Franklin Lakes, NJ) to remove cell clumps and bone particles, and resuspended in HBSS at 10 6 cells/ml. Bone marrow leukocytes were resuspended in 3 ml of 45% Percoll solution and layered on top of a Percoll gradient consisting of 2 ml each of 50, 55, 62, and 81% Percoll solutions in a conical 15-ml polypropylene tube. The gradient was centrifuged at 1600g for 30 min at 108C, and the cell band located between the 61 and 81% Percoll layers was collected. The cells were washed, layered on top of 3 ml of Histopaque 1119, and centrifuged at 1600g for 30 min at 108C to remove contaminating red blood cells. The purified neutrophils were collected, washed, and resuspended in HBSS. All animal use was conducted in accordance with a protocol approved by the Institutional Animal Care and Use Committee at Montana State University. a EC 50 values represent the average of means from three independent experiments and were determined by nonlinear regression analysis of the concentration-response curves (5-6 points) generated using GraphPad Prism 5 with 95% confidential interval (P < 0.05). Efficacy is expressed as % of the response induced by 5 nM fMLF (FPR1), 5 nM WKYMVm (FPR2), or 10 nM WKYMVM (FPR3). b N.A., no activity (no response was observed during the first 2 min after addition of compounds under investigation) considering the limits of efficacy > 20% and EC 50 < 50 mM. 21 were measured with a FlexStation II scanning fluorometer using a FLIPR 3 calcium assay kit (Molecular Devices, Sunnyvale, CA) for human and murine neutrophils, as well as HL60 and RBL cells, as described previously . All active compounds were evaluated in wild-type HL60 and RBL cells to verify that the agonists are inactive in non-transfected cells. Neutrophils or HL60 and RBL cells, suspended in HBSS 2 containing 10 mM HEPES, were loaded with Fluo-4 AM dye (Invitrogen; 1.25 lg/mL final concentration) and incubated for 30 min in the dark at 378C. After dye loading, the cells were washed with HBSS 2 containing 10 mM HEPES, resuspended in HBSS containing 10 mM HEPES and Ca 21 and Mg 21 (HBSS 1 ), and aliquotted into the wells of a flat-bottomed, half-area-well black microtiter plates (2 3 10 5 cells/well). The compound of interest was added from a source plate containing dilutions of test compounds in HBSS 1 , and changes in fluorescence were monitored (k ex 5 485 nm, k em 5 538 nm) every 5 s for 240 s at room temperature after automated addition of compounds. Maximum change in fluorescence, expressed in arbitrary units over baseline, was used to determine agonist response. Responses were normalized to the response induced by 5 nM fMLF (Sigma Chemical Co., St. Louis, MO) for FPR1 HL60 cells and human neutrophils, 5 nM WKYMVm (Calbiochem, San Diego, CA) for FPR2 HL60 cells, 10 nM WKYMVM (Tocris Bioscience) for FPR3-HL60 cells, and 10 nM WKYMVm for mouse neutrophils, mFpr1-RBL, and mFpr2-RBL cells, which were assigned a value of 100%. Curve fitting (5-6 points) and calculation of median effective concentration values (EC 50 values) were performed using nonlinear regression analysis of the concentration-response curves generated using Prism 5 (GraphPad Software, Inc., San Diego, CA).
Changes in intracellular Ca
Cell Migration Assay
Neutrophils were suspended in HBSS 1 containing 2% (v/v) FBS (2 3 10 6 cells/mL), and cell migration was analyzed in 96-well ChemoTx chemotaxis chambers (Neuroprobe, Gaithersburg, MD), as previously described [Schepetkin et al., 2014b] . Briefly, (95) a EC 50 values represent the average of means from three independent experiments and were determined by nonlinear regression analysis of the concentration-response curves (5-6 points) generated using GraphPad Prism 5 with 95% confidential interval (P < 0.05). Efficacy is expressed as % of the response induced by 5 nM fMLF (FPR1-HL60), 5 nM WKYMVm (FPR2-HL60), or 10 nM WKYMVM (FPR3-HL60).
b N.A., no activity (no response was observed during first 2 min after addition of compounds under investigation) considering the limits of efficacy > 20% and EC 50 < 50 mM.
lower wells were loaded with 30 mL of HBSS 1 containing 2% (v/v) FBS and the indicated concentrations of test compound, DMSO (negative control), or 1 nM fMLF as a positive control. Neutrophils were added to the upper wells and allowed to migrate through the 5.0 mm pore polycarbonate membrane filter for 60 min at 378C and 5% CO 2 . The number of migrated cells was determined by measuring ATP in lysates of transmigrated cells using a luminescencebased assay (CellTiter-Glo; Promega, Madison, WI), and luminescence measurements were converted to absolute cell numbers by comparison of the values with standard curves obtained with known numbers of neutrophils. The results are expressed as percentage of negative control and were calculated as follows: (number of cells migrating in response to test compounds/spontaneous migration in response to control medium)3100. EC 50 values were determined by nonlinear regression analysis of the concentrationresponse curves generated using Prism 5 software.
RESULTS AND DISCUSSION
The newly synthesized compounds were evaluated for their ability to induce intracellular Ca 21 flux in human neutrophils and HL60 cells transfected with FPR1, FPR2, and FPR3 (Tables 1-3) . Compounds were also evaluated in mouse neutrophils and RBL-2H3 cells transfected with mouse FPR1 and FPR2. To verify receptor specificity, these compounds were also evaluated, as applicable, in wild-type non-transfected HL60 and RBL cells and were found to be inactive. a EC 50 values represent the average of means from three independent experiments and were determined by nonlinear regression analysis of the concentration-response curves (5-6 points) generated using GraphPad Prism 5 with 95% confidential interval (P < 0.05). Efficacy is expressed as % of the response induced by 5 nM fMLF (FPR1-HL60), 5 nM WKYMVm (FPR2-HL60), or 10 nM WKYMVM (FPR3-HL60).
b N.A., no activity (no response was observed during first 2 min after addition of compounds under investigation) considering the limits of efficacy > 20% and EC 50 < 50 mM. a The data are presented as the mean 6 SD of three independent experiments with cells from different donors, in which median effective concentration values (EC 50 ) were determined by nonlinear regression analysis of the concentration-response curves (5-6 points) generated using GraphPad Prism 5 with 95% confidential interval (P < 0.05).
In the 4-benzylpyridazinone series (Table 1) , the introduction of a methyl at C-5 was associated with high FPR agonist activity (compounds 4a,b) leading to some of themost potent mixed agonists. For example, 4a activated all three FPR subtypes with good potency (FPR1 EC 50 5 19 nM, FPR2 EC 50 5 43 nM, FPR3 EC 50 5 40 nM). Although 4b was an FPR1 and FPR3 agonist with submicromolar activity (EC 50 5 0.9 and 0.13 mM, respectively), it exhibited a preference for FPR2 (EC 50 5 13 nM).These results are consistent with our previous studies [Cilibrizzi et al., 2009] , which showed that when OCH 3 was shifted from the meta to the para position of the benzyl at C-4, the selectivity of a given ligand shifted from mixed FPR1/FPR2 to FPR2-specific.
Elongation of the aliphatic chain (compounds 4c-e) was detrimental for activity and led to mixed agonists with EC 50 values in the micromolar range, with the exception of the 3-butyl derivative 4e, which was a weak but selective FPR2 agonist (EC 50 5 15.7 mM). Surprisingly, the 5-phenyl derivative 4f exhibited FPR1 selectivity (EC 50 5 2.2 mM, Table 1 ).
As shown in Table 2 elimination of the substituent at position 4 and introduction of CH 3 or C 6 H 5 at C-5 (products of type 6 and 7) led to compounds endowed with micromolar activity and a slight preference for FPR2. The unsaturation at C-4/C-5 of the heterocyclic ring (7a,b) appeared to be associated with increased agonist activity and selectivity (generally submicromolar range) relative to the 4,5-dihydro analogues, (6)6a,b. As compounds (6)6a,b were mixtures of isomers, it is possible that one of the isomers could be more active than the other, reducing overall specific activity or even interfering with binding of the active isomer. Table 3 reports the activities of the 2-oxothiazole derivatives, 9a-h and 10 that exhibited EC 50 values in the micromolar range for the three FPR isoforms, with the exception of compound 9d, which had EC 50 values of 0.28 mM and 0.23 mM for FPR1 and FPR2, respectively. No appreciable FPR2 selectivity was observed for this series, although they did have a lower affinity for FPR3 (EC 50 20-fold higher than for FPR1 and FPR2).
The most active derivatives (4a,b and 7b) were also evaluated for their chemoattractant activity toward human neutrophils (Table 4) . As expected for FPR agonists, they stimulated neutrophil migrations with EC 50 values that correlated well with their ability to induce human neutrophil intracellular Ca 21 flux. All of the synthesized compounds were also evaluated in mouse neutrophils and RBL cells transfected with mouse Fpr1 or Fpr2 (Table 5 ). The majority of tested compounds had no agonist effects at mouse neutrophils or RBL cells transfected with mouse Fpr; however, four compounds were active in mouse neutrophils and three had activity in either Fpr1 or Fpr2 RBL cells. As shown in Table 5 , compounds 4f, (6)6a,b, and 7a,b all activated Ca 21 flux in mouse neutrophils with low micromolar activity. From the literature, it is well known that there are differences in affinity between FPR1 and Fpr1 for fMLF and other FPR agonists/antagonists [He et al., 2000] and these receptors have only 72% sequence similarities [Dahlgren et al., 2016] . However, it is difficult to explain the complete inactivity of the most potent human FPR agonists of this series (4a and 4b) toward mouse neutrophils or mouse Fprtransfected RBL cells. Comparison of the results between human FPR-transfected HL60 cells and mouse Fpr1/Fpr2-transfected RBL cells was also difficult to interpret. For example, (6)6a was active for all human FPR and mouse Fpr subtypes tested, whereas 4f was inactive in FPR2-HL60 cells but had an EC 50 value of 28.8 mM for mouse Fpr2. Likewise, (6)6a was active for all human FPR subtypes but only activated mFpr1 and not mouse neutrophils or mFpr2. Thus, the difference in human and mouse FPR responses to various agonists are clearly evident and will need to be considered when using agonists in mouse models involving Fpr function.
In conclusion, we have identified a new series of FPRs agonists with EC 50 values in the nanomolar to low micromolar range. The majority of compounds were mixed FPRs agonists, but with a slight 
